Bluebird Bio (BLUE), Carlyle (CG), SK Capital Partners, and Beacon Parent Holdings announced that all required regulatory approvals to complete the previously announced acquisition of the Company by Carlyle and SK Capital have been received. No further regulatory approvals are required to complete the transaction. The parties expect to complete the merger promptly following the successful completion of the ongoing tender offer, which is scheduled to expire one minute after 11:59 p.m. New York City time on May 12, 2025, unless the tender offer is further extended or earlier terminated. Under the terms of the merger agreement, stockholders will receive an upfront payment of $3.00 per share in cash and a contingent value right of $6.84 per share in cash payable upon achievement of a net sales milestone, for a total potential value of $9.84 per share. The bluebird board of directors unanimously recommends that stockholders tender into the offer.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLUE:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue